Comparison of estimated human dose of 111 In-rituximab by MCNPX code and MIRD method based on mice data Comparison of 111 In-rituximab dose by MCNPX and MIRD
Archives of Advances in Biosciences,
Vol. 12 No. 2 (2021),
9 May 2021
,
Page 40-46
https://doi.org/10.22037/aab.v12i2.34593
Abstract
Introduction: Radiopharmaceuticals are widely used in modern treatment of cancer. The injection of radiopharmaceuticals into the patient’s body and its accumulation in target tissue should have most therapeutic effect on target tissue. The purpose of this study is to calculate the effective absorbed dose of labeled 111 In-rituximab in human body based on mice biodistribution data by MCNPX code and MIRD method.
Materials and Methods: In this investigation, first, the accumulated activity was computed for mice source organs then it was converted into accumulated activity for human source organs via Sparks and Aydogan formula. After that, the equivalent and effective dose were calculated using MCNPX code and the Medical Internal Radiation Dose (MIRD) method.
Results: The results of the effective absorbed dose in human body showed that the highest absorbed dose concentrated in lungs. Although our results were different, they were in good agreement with the literature on this subject.
Conclusion: According to the results of the study, based on the effective absorbed dose, using MIRD method the highest received dose was identified to be in lung, kidney, spleen, pancreas, heart, stomach, liver and intestine, respectively.
- Indium-111, Rituximab, Effective absorbed dose, Monte Carlo simulation, MIRD method
How to Cite
References
Rhodes BA, Croft BY. Basics of radiopharmacy: Mosby; 1978.
Khan FM, Gibbons JP. Khan's the physics of radiation therapy: Lippincott Williams & Wilkins; 2014.
Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. The lancet oncology. 2007;8(7):587-94.
Haugen BR, Lin EC. Isotope imaging for metastatic thyroid cancer. Endocrinology and Metabolism Clinics. 2001;30(2):469-92.
Lakshmanan MN, Harrawood BP, Agasthya GA, Kapadia AJ. Simulations of breast cancer imaging using gamma-ray stimulated emission computed tomography. IEEE transactions on medical imaging. 2013;33(2):546-55.
Yang DJ, Kim EE, Inoue T. Targeted molecular imaging in oncology. Annals of nuclear medicine. 2006;20(1):1.
Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131I whole body scan: comparison of patients treated with high 131I activities versus untreated patients. The Journal of Clinical Endocrinology & Metabolism. 2001;86(9):4092-7.
Argyrou M, Valassi A, Andreou M, Lyra M. Rhenium-188 production in hospitals, by w-188/re-188 generator, for easy use in radionuclide therapy. International Journal of Molecular Imaging. 2013;2013.
Blower P, Kettle A, O'doherty M, Coakley A, Knapp Jr F. 99m Tc (V) DMSA quantitatively predicts 188 Re (V) DMSA distribution in patients with prostate cancer metastatic to bone. European journal of nuclear medicine. 2000;27(9):1405-9.
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology. 2008;26(13):2124-30.
Perik PJ, Lub-De Hooge MN, Gietema JA, Van der Graaf W, de Korte MA, Jonkman S, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24(15):2276-82.
Shirmardi SP, Erfani M, Mazidi M. Preparation and evaluation of 67Ga-DOTA-Bombesin (7-14) as a tumor scintigraphic agent. 2011.
Shanehsazzadeh S, Lahooti A, Shirmardi SP, Erfani M. Comparison of estimated human effective dose of 67 Ga-and 99m Tc-labeled bombesin based on distribution data in mice. Journal of Radioanalytical and Nuclear Chemistry. 2015;305(2):513-20.
Cornelissen B, A Vallis K. Targeting the nucleus: an overview of Auger-electron radionuclide therapy. Current drug discovery technologies. 2010;7(4):263-79.
Eisenbeis CF, Caligiuri MA, Byrd JC. Rituximab: converging mechanisms of action in non-Hodgkin’s lymphoma? Clinical Cancer Research. 2003;9(16):5810-2.
Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, The Journal of the American Society of Hematology. 1997;90(6):2188-95.
Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab—the world’s first oncology monoclonal antibody therapy. Frontiers in oncology. 2018;8:163.
Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood, The Journal of the American Society of Hematology. 1998;91(5):1644-52.
Sharon J, Liebman MA, Williams BR. Recombinant polyclonal antibodies for cancer therapy. Journal of cellular biochemistry. 2005;96(2):305-13.
Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR journal. 2005;46(3):258-68.
Shanehsazzadeh S, Oghabian MA, Lahooti A, Abdollahi M, Haeri SA, Amanlou M, et al. Estimated background doses of [67Ga]-DTPA-USPIO in normal Balb/c mice as a potential therapeutic agent for liver and spleen cancers. Nuclear medicine communications. 2013;34(9):915-25.
Lahooti A, Shanehsazzadeh S, Jalilian AR, Tavakoli MB. Assessment of effective absorbed dose of 111In-DTPA-Buserelin in human on the basis of biodistribution rat data. Radiation protection dosimetry. 2013;154(1):1-8.
Khorrami Moghaddam A, Reza Jalilian A, Hayati V, Shanehsazzadeh S. Determination of human absorbed dose of 201Tl (III)-DTPA-HIgG based on biodistribution data in rats. Radiation protection dosimetry. 2010;141(3):269-74.
Rezaeejam H, HAKIMI A, Jalilian A, Abbasian P, SHIRVANI AS, GHANNADI MM. Determination of human absorbed dose from [153Sm]-Samarium maltolate based on distribution data in rats. 2015.
Cheki M, Papie M, Mansi L, Kitson S, Gali H. Preliminary Human Radiation Dose Estimates of PET Renal Agents, Para-18F-Fluorohippuric Acid and Ortho-124I-Iodohippuric Acid from Rat Biodistribution Data. Current radiopharmaceuticals. 2018;11(1):58-63.
Pelowitz DB. MCNPXTM user’s manual. Los Alamos National Laboratory, Los Alamos. 2005.
Bacher M, Depboylu C, Du Y, Noelker C, Oertel WH, Behr T, et al. Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Neuroscience letters. 2009;449(3):240-5.
Jalilian AR, Sardari D, Kia L, Rowshanfarzad P, Garousi J, Akhlaghi M, et al. Preparation, quality control and biodistribution studies of two [111In]-rituximab immunoconjugates. Scientia Pharmaceutica. 2008;76(2):151-70.
Bagheri R, Afarideh H, Ghannadi-Maragheh M, Bahrami-Samani A, Shirmardi SP. Dosimetric study of radium-223 chloride and 153Sm-EDTMP for treatment of bone metastases using MCNPX code and available experimental data. Journal of Radioanalytical and Nuclear Chemistry 303(3):1991-1998.
Bagheri R, Afarideh H, Ghannadi-Maragheh M, Shirmardi SP, Bahrami-Samani A. Study of Bone Surface Absorbed Dose in Treatment of Bone Metastases via Selected Radiopharmaceuticals: Using MCNP4C Code and Available Experimental Data. Cancer Biotherapy and Radiopharmaceuticals 2015 30:4, 174-181.
- Abstract Viewed: 118 times
- PDF Downloaded: 104 times